NASDAQ:LOXO - Loxo Oncology Stock Price, Price Target & More

$129.51 -3.55 (-2.67 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$129.51
Today's Range$128.78 - $135.00
52-Week Range$42.11 - $138.54
Volume302,266 shs
Average Volume388,459 shs
Market Capitalization$4.00 billion
P/E Ratio-24.39
Dividend YieldN/A
Beta2.32

About Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology logoLoxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Receive LOXO News and Ratings via Email

Sign-up to receive the latest news and ratings for LOXO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LOXO
CUSIPN/A
Phone203-653-3880

Debt

Debt-to-Equity RatioN/A
Current Ratio3.53%
Quick Ratio3.53%

Price-To-Earnings

Trailing P/E Ratio-24.39
Forward P/E Ratio431.70
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.30 million
Price / Sales182.59
Cash FlowN/A
Price / CashN/A
Book Value$12.63 per share
Price / Book10.25

Profitability

EPS (Most Recent Fiscal Year)($5.31)
Net Income$-148,870,000.00
Net MarginsN/A
Return on Equity-29.58%
Return on Assets-22.72%

Miscellaneous

Employees59
Outstanding Shares30,030,000

How to Become a New Pot Stock Millionaire

Loxo Oncology (NASDAQ:LOXO) Frequently Asked Questions

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology (NASDAQ:LOXO) posted its earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.22) by $0.53. The biopharmaceutical company earned $21.30 million during the quarter. View Loxo Oncology's Earnings History.

What price target have analysts set for LOXO?

11 Wall Street analysts have issued 12-month price objectives for Loxo Oncology's shares. Their forecasts range from $95.00 to $170.00. On average, they anticipate Loxo Oncology's share price to reach $129.8750 in the next year. View Analyst Ratings for Loxo Oncology.

What are Wall Street analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:
  • 1. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (3/9/2018)
  • 2. Cann analysts commented, "Loxo’s Q4:17 loss per share was $0.69 compared to our estimated loss of $1.18. The lower than estimated loss resulted from collaboration revenue recognition of $21.3 million. This was partially offset by operating expenses being 17.9% higher than estimated. Higher operating expenses arose primarily from higher R&D. As a result, we are increasing our estimated R&D expenses for 2018 and 2019. There were no other remarkable variances in the quarter. The completion of the rolling NDA submission for larotrectinib is expected in March 2018, and the Marketing Authorization Application submission in the EU is expected in 2018. This submission is being led by Bayer." (3/1/2018)
  • 3. BTIG Research analysts commented, "Today LOXO announced the acquisition of REDX08608 (LOXO-305) from Redx Pharma (REDX, Not Rated), a reversible BTK inhibitor that is effective against both wild-type and mutant C481S BTK. We view the acquisition of REDX08608 positively, as the ~$40m upfront acquisition cost is relatively devoid of downstream payments (milestones etc.), and despite the BTK space being competitive with next generation programs to ibrutinib, we think there will be ample room for multiple BTK inhibitors and we also favor the selectivity of LOXO-305. Management has guided for the submission of an IND during 2018. We reiterate our Buy rating and $75 PT." (8/3/2017)

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:
  • Dr. Joshua H. Bilenker M.D., Founder, Chief Exec. Officer, Pres and Director (Age 46)
  • Ms. Jennifer Burstein, Principal Financial Officer & Sr. VP of Fin. (Age 46)
  • Mr. Jacob S. Van Naarden, Chief Bus. Officer (Age 33)
  • Dr. Lori Anne Kunkel, Consultant and Director (Age 60)
  • Ms. Sara Slifka, VP of Bus. Operations & Program Management

Has Loxo Oncology been receiving favorable news coverage?

News stories about LOXO stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Loxo Oncology earned a daily sentiment score of 0.16 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.81 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Loxo Oncology's major shareholders?

Loxo Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include ACCESS INDUSTRIES MANAGEMENT, LLC (5.82%) and ACCESS INDUSTRIES MANAGEMENT, LLC (5.82%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Institutional Ownership Trends for Loxo Oncology.

How do I buy shares of Loxo Oncology?

Shares of LOXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of LOXO stock can currently be purchased for approximately $129.51.

How big of a company is Loxo Oncology?

Loxo Oncology has a market capitalization of $4.00 billion and generates $21.30 million in revenue each year. The biopharmaceutical company earns $-148,870,000.00 in net income (profit) each year or ($5.31) on an earnings per share basis. Loxo Oncology employs 59 workers across the globe.

How can I contact Loxo Oncology?

Loxo Oncology's mailing address is 281 TRESSER BLVD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company can be reached via phone at 203-653-3880 or via email at [email protected]


MarketBeat Community Rating for Loxo Oncology (LOXO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe LOXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOXO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Loxo Oncology (NASDAQ:LOXO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Loxo Oncology in the last 12 months. Their average twelve-month price target is $129.8750, suggesting that the stock has a possible upside of 0.28%. The high price target for LOXO is $170.00 and the low price target for LOXO is $95.00. There are currently 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.093.003.112.88
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $129.8750$121.50$92.00$79.69
Price Target Upside: 0.28% upside0.37% downside24.39% upside6.28% downside

Loxo Oncology (NASDAQ:LOXO) Consensus Price Target History

Price Target History for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ:LOXO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018Morgan StanleyUpgradeEqual Weight -> Overweight$130.00 -> $170.00HighView Rating Details
4/16/2018William BlairReiterated RatingBuyHighView Rating Details
3/5/2018CitigroupReiterated RatingBuy -> Buy$108.00 -> $151.00HighView Rating Details
3/2/2018Stifel NicolausReiterated RatingBuy$135.00HighView Rating Details
3/1/2018CannReiterated RatingBuy$122.00HighView Rating Details
2/22/2018CIBCInitiated CoverageOutperform -> Outperform$132.00LowView Rating Details
2/22/2018OppenheimerInitiated CoverageOutperform$132.00LowView Rating Details
11/14/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$77.18 -> $95.00N/AView Rating Details
11/14/2017Ifs SecuritiesUpgradeOutperform -> Strong-BuyN/AView Rating Details
9/29/2017BTIG ResearchReiterated RatingBuy$75.00 -> $102.00LowView Rating Details
9/28/2017CowenReiterated RatingBuyLowView Rating Details
2/8/2017Jefferies GroupInitiated CoverageBuy$50.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Loxo Oncology (NASDAQ:LOXO) Earnings History and Estimates Chart

Earnings by Quarter for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ:LOXO) Earnings Estimates

2018 EPS Consensus Estimate: ($4.23)
2019 EPS Consensus Estimate: $1.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.19)($0.79)($0.99)
Q2 20182($1.22)($0.88)($1.05)
Q3 20182($1.26)($1.18)($1.22)
Q4 20182($1.12)($0.81)($0.97)
Q1 20191($0.90)($0.90)($0.90)
Q2 20191($0.90)($0.90)($0.90)
Q3 20191$1.62$1.62$1.62
Q4 20191$1.56$1.56$1.56

Loxo Oncology (NASDAQ LOXO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018Q4 2017($1.22)($0.69)$21.30 millionViewListenView Earnings Details
11/2/2017Q3 2017($1.38)($1.12)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.99)($1.14)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.76)($0.96)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.85)($1.28)ViewN/AView Earnings Details
11/2/2016Q316($0.74)($0.82)ViewN/AView Earnings Details
8/3/2016Q2($0.63)($0.77)ViewN/AView Earnings Details
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details
9/12/2014Q2 2014($12.27)($14.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Loxo Oncology (NASDAQ:LOXO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Loxo Oncology (NASDAQ LOXO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.80%
Insider Trading History for Loxo Oncology (NASDAQ:LOXO)
Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ LOXO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2018Lori Anne KunkelDirectorSell5,000$132.68$663,400.0010,940View SEC Filing  
3/14/2018Joshua H BilenkerCEOSell15,000$131.54$1,973,100.00190,207View SEC Filing  
3/14/2018Naarden Jacob VanInsiderSell3,082$131.41$405,005.621,541View SEC Filing  
3/13/2018Jennifer BursteinVPSell1,700$131.33$223,261.001,700View SEC Filing  
2/13/2018Joshua H BilenkerCEOSell15,000$96.57$1,448,550.00190,207View SEC Filing  
2/13/2018Naarden Jacob VanInsiderSell3,082$96.34$296,919.881,541View SEC Filing  
2/12/2018Jennifer BursteinVPSell1,700$93.24$158,508.001,700View SEC Filing  
1/22/2018Avi Z NaiderDirectorSell15,000$100.00$1,500,000.00141,118View SEC Filing  
1/17/2018Joshua H BilenkerCEOSell15,000$88.21$1,323,150.00190,207View SEC Filing  
1/17/2018Naarden Jacob VanInsiderSell3,082$88.21$271,863.221,541View SEC Filing  
1/16/2018Jennifer BursteinVPSell1,500$87.50$131,250.001,500View SEC Filing  
12/20/2017Timothy M. MaylebenDirectorSell10,000$80.49$804,900.00View SEC Filing  
12/19/2017Aisling Capital Iii LpMajor ShareholderSell250,000$80.50$20,125,000.00View SEC Filing  
12/15/2017Joshua H BilenkerCEOSell15,000$81.12$1,216,800.00190,207View SEC Filing  
12/15/2017Naarden Jacob VanInsiderSell3,082$81.19$250,227.581,541View SEC Filing  
12/14/2017Jennifer BursteinVPSell1,700$83.27$141,559.001,700View SEC Filing  
12/8/2017David P BonitaDirectorSell250,000$82.50$20,625,000.00View SEC Filing  
11/28/2017Joshua H BilenkerCEOSell15,000$74.45$1,116,750.00182,707View SEC Filing  
11/28/2017Naarden Jacob VanInsiderSell3,082$74.50$229,609.001,541View SEC Filing  
11/27/2017Jennifer BursteinVPSell1,700$74.82$127,194.001,700View SEC Filing  
11/22/2017Aisling Capital Iii LpMajor ShareholderSell500,000$75.00$37,500,000.00View SEC Filing  
11/22/2017Orbimed Advisors LlcDirectorSell267,000$75.00$20,025,000.0013,000View SEC Filing  
11/20/2017Keith T FlahertyDirectorSell7,250$75.99$550,927.5012,493View SEC Filing  
11/16/2017Orbimed Advisors LlcDirectorSell270,000$74.26$20,050,200.00View SEC Filing  
11/2/2017Lori Anne KunkelDirectorSell5,000$84.91$424,550.0015,040View SEC Filing  
10/31/2017Joshua H BilenkerCEOSell7,500$86.49$648,675.00196,207View SEC Filing  
10/31/2017Naarden Jacob VanInsiderSell1,541$86.52$133,327.321,541View SEC Filing  
10/30/2017Jennifer BursteinVPSell1,700$87.19$148,223.001,700View SEC Filing  
10/16/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00144,118View SEC Filing  
9/19/2017Joshua H BilenkerCEOSell15,000$89.02$1,335,300.00196,207View SEC Filing  
9/19/2017Naarden Jacob VanInsiderSell3,082$89.00$274,298.001,541View SEC Filing  
9/18/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00149,118View SEC Filing  
9/18/2017Jennifer BursteinVPSell1,700$89.10$151,470.001,700View SEC Filing  
9/18/2017Joshua H BilenkerCEOSell7,500$89.25$669,375.00196,207View SEC Filing  
9/18/2017Naarden Jacob VanInsiderSell1,541$89.20$137,457.201,541View SEC Filing  
9/13/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00154,118View SEC Filing  
8/22/2017Lori Anne KunkelDirectorSell10,000$75.17$751,700.0016,840View SEC Filing  
8/21/2017Keith T FlahertyDirectorSell7,250$72.26$523,885.0020,432View SEC Filing  
8/15/2017Joshua H BilenkerCEOSell15,000$73.56$1,103,400.00196,207View SEC Filing  
8/15/2017Naarden Jacob VanInsiderSell3,082$73.57$226,742.741,541View SEC Filing  
8/14/2017Jennifer BursteinVPSell1,700$73.73$125,341.001,700View SEC Filing  
8/14/2017Joshua H BilenkerCEOSell7,500$73.73$552,975.00196,207View SEC Filing  
8/14/2017Naarden Jacob VanInsiderSell1,541$73.73$113,617.931,541View SEC Filing  
5/22/2017Keith T FlahertyDirectorSell7,250$45.09$326,902.5027,141View SEC Filing  
1/10/2017Aisling Capital Iii LpMajor ShareholderBuy160,000$31.00$4,960,000.00View SEC Filing  
12/19/2016Keith T FlahertyDirectorSell7,250$30.23$219,167.5038,732View SEC Filing  
9/7/2016Keith T FlahertyDirectorSell14,500$30.00$435,000.0045,982View SEC Filing  
8/11/2016Keith T FlahertyDirectorSell15,000$26.00$390,000.0060,482View SEC Filing  
8/10/2016David P BonitaDirectorSell447,857$26.96$12,074,224.72View SEC Filing  
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50159,118View SEC Filing  
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Loxo Oncology (NASDAQ LOXO) News Headlines

Source:
DateHeadline
Insider Selling: Loxo Oncology (LOXO) Director Sells 5,000 Shares of StockInsider Selling: Loxo Oncology (LOXO) Director Sells 5,000 Shares of Stock
www.americanbankingnews.com - April 24 at 7:32 PM
How Blueprint Medicines Got The BluesHow Blueprint Medicines Got The Blues
www.forbes.com - April 24 at 8:46 AM
Loxo Oncology (LOXO) Receives Consensus Recommendation of "Buy" from BrokeragesLoxo Oncology (LOXO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 19 at 3:32 PM
Loxo Oncology (LOXO) Shares March Higher, Can It Continue?Loxo Oncology (LOXO) Shares March Higher, Can It Continue?
finance.yahoo.com - April 17 at 5:28 PM
UPDATE: Morgan Stanley Upgrades Loxo Oncology (LOXO) to Overweight Citing Potential RET DifferentiationUPDATE: Morgan Stanley Upgrades Loxo Oncology (LOXO) to Overweight Citing Potential RET Differentiation
www.streetinsider.com - April 17 at 9:07 AM
$23.30 Million in Sales Expected for Loxo Oncology (LOXO) This Quarter$23.30 Million in Sales Expected for Loxo Oncology (LOXO) This Quarter
www.americanbankingnews.com - April 17 at 3:29 AM
Loxo Oncology (LOXO) Upgraded by Morgan Stanley to OverweightLoxo Oncology (LOXO) Upgraded by Morgan Stanley to Overweight
www.americanbankingnews.com - April 16 at 7:39 AM
William Blair Reaffirms "Buy" Rating for Loxo Oncology (LOXO)William Blair Reaffirms "Buy" Rating for Loxo Oncology (LOXO)
www.americanbankingnews.com - April 16 at 7:03 AM
 Brokerages Anticipate Loxo Oncology (LOXO) to Post $0.08 Earnings Per Share Brokerages Anticipate Loxo Oncology (LOXO) to Post $0.08 Earnings Per Share
www.americanbankingnews.com - April 15 at 1:23 PM
Loxo Oncologys (LOXO) "Buy" Rating Reiterated at BTIG ResearchLoxo Oncology's (LOXO) "Buy" Rating Reiterated at BTIG Research
www.americanbankingnews.com - April 13 at 9:58 PM
Stifel Nicolaus Reiterates Buy Rating for Loxo Oncology (LOXO)Stifel Nicolaus Reiterates Buy Rating for Loxo Oncology (LOXO)
www.americanbankingnews.com - April 13 at 9:27 PM
Loxo Oncology (LOXO) Upgraded at Zacks Investment ResearchLoxo Oncology (LOXO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 12 at 4:31 PM
Stifel Nicolaus Reaffirms "Buy" Rating for Loxo Oncology (LOXO)Stifel Nicolaus Reaffirms "Buy" Rating for Loxo Oncology (LOXO)
www.americanbankingnews.com - April 11 at 5:01 PM
Veracyte Announces Precision Medicine Collaboration With Loxo OncologyVeracyte Announces Precision Medicine Collaboration With Loxo Oncology
www.businesswire.com - April 11 at 9:13 AM
Loxo teams up with Veracyte to advance development of therapies for genetically defined cancersLoxo teams up with Veracyte to advance development of therapies for genetically defined cancers
seekingalpha.com - April 11 at 9:13 AM
BRIEF-Veracyte Announces Precision Medicine Collaboration With Loxo OncologyBRIEF-Veracyte Announces Precision Medicine Collaboration With Loxo Oncology
www.reuters.com - April 11 at 9:13 AM
Illumina, Loxo Oncology Announce CollaborationIllumina, Loxo Oncology Announce Collaboration
www.finanznachrichten.de - April 10 at 9:05 AM
Loxo Oncology (LOXO), Illumina (ILMN) to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion DiagnosticsLoxo Oncology (LOXO), Illumina (ILMN) to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
www.streetinsider.com - April 10 at 9:05 AM
Illumina and Loxo Oncology team up to develop NGS-based pan-cancer companion diagnostic testIllumina and Loxo Oncology team up to develop NGS-based pan-cancer companion diagnostic test
seekingalpha.com - April 10 at 9:05 AM
Illumina, Loxo Oncology Announce Collaboration - Quick FactsIllumina, Loxo Oncology Announce Collaboration - Quick Facts
www.nasdaq.com - April 10 at 9:05 AM
BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion DiagnosticsBRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics
www.reuters.com - April 10 at 9:05 AM
Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion DiagnosticsLoxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
finance.yahoo.com - April 10 at 9:05 AM
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion DiagnosticsIllumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
finance.yahoo.com - April 10 at 9:05 AM
Loxo, Illumina to partner for diagnostic tool targeting cancerLoxo, Illumina to partner for diagnostic tool targeting cancer
finance.yahoo.com - April 10 at 9:05 AM
Loxo and Illumina in partnership over diagnostic for cancer drugLoxo and Illumina in partnership over diagnostic for cancer drug
finance.yahoo.com - April 10 at 9:05 AM
JMP Securities Downgrades Loxo Oncology (LOXO) to Market PerformJMP Securities Downgrades Loxo Oncology (LOXO) to Market Perform
www.americanbankingnews.com - April 9 at 8:06 PM
Loxo Oncology (LOXO) Announces Acceptance of LOXO-292 Oral Presentation at ASCOLoxo Oncology (LOXO) Announces Acceptance of LOXO-292 Oral Presentation at ASCO
www.streetinsider.com - April 6 at 9:00 AM
Today’s Research Reports on Stocks to Watch: Loxo Oncology and Boston ScientificToday’s Research Reports on Stocks to Watch: Loxo Oncology and Boston Scientific
finance.yahoo.com - April 5 at 10:51 AM
Loxo Oncology (LOXO) Upgraded to Buy at ValuEngineLoxo Oncology (LOXO) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 12:11 PM
FOCUS-High-flying biotech Loxo tempers bullish view for cancer drugFOCUS-High-flying biotech Loxo tempers bullish view for cancer drug
finance.yahoo.com - April 3 at 8:57 AM
High-flying biotech Loxo tempers bullish view for cancer drugHigh-flying biotech Loxo tempers bullish view for cancer drug
finance.yahoo.com - April 3 at 8:57 AM
Zacks: Brokerages Anticipate Loxo Oncology (LOXO) Will Announce Quarterly Sales of $23.30 MillionZacks: Brokerages Anticipate Loxo Oncology (LOXO) Will Announce Quarterly Sales of $23.30 Million
www.americanbankingnews.com - March 31 at 2:28 AM
Zacks: Analysts Anticipate Loxo Oncology Inc (LOXO) to Announce -$0.44 Earnings Per ShareZacks: Analysts Anticipate Loxo Oncology Inc (LOXO) to Announce -$0.44 Earnings Per Share
www.americanbankingnews.com - March 29 at 5:22 PM
Blog Exposure - Loxo Oncology Completed Rolling Submission of NDA to the FDA for Larotrectinib for TRK Fusion Cancer TreatmentBlog Exposure - Loxo Oncology Completed Rolling Submission of NDA to the FDA for Larotrectinib for TRK Fusion Cancer Treatment
finance.yahoo.com - March 28 at 9:02 AM
Loxo Oncology (LOXO) Completes Rolling Submission of NDA to FDA for Larotrectinib for Treatment of TRK Fusion CancerLoxo Oncology (LOXO) Completes Rolling Submission of NDA to FDA for Larotrectinib for Treatment of TRK Fusion Cancer
www.streetinsider.com - March 27 at 9:06 AM
Loxo Oncology (LOXO) Upgraded to "Buy" by BidaskClubLoxo Oncology (LOXO) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
Loxo Oncology Completes Rolling Submission of New Drug Application to US Food and Drug Administration for ...Loxo Oncology Completes Rolling Submission of New Drug Application to US Food and Drug Administration for ...
globenewswire.com - March 26 at 4:51 PM
BRIEF-Loxo Oncology Completes Rolling Submission Of New Drug Application To U.S. Food And Drug AdministrationBRIEF-Loxo Oncology Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration
www.reuters.com - March 26 at 9:02 AM
Loxo Oncology completes U.S. application for larotrectinib in NTRK-positive solid tumorsLoxo Oncology completes U.S. application for larotrectinib in NTRK-positive solid tumors
seekingalpha.com - March 26 at 9:02 AM
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion CancerBayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
finance.yahoo.com - March 26 at 9:02 AM
Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion CancerLoxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer
finance.yahoo.com - March 26 at 9:02 AM
Loxo Oncology Inc (LOXO) Receives Consensus Recommendation of "Buy" from BrokeragesLoxo Oncology Inc (LOXO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 3:36 PM
Morgan Stanley Lowers Loxo Oncology (LOXO) to Equal WeightMorgan Stanley Lowers Loxo Oncology (LOXO) to Equal Weight
www.americanbankingnews.com - March 21 at 6:40 PM
Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics - BenzingaTurning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics - Benzinga
www.benzinga.com - March 21 at 5:14 PM
Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood TherapeuticsTurning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics
finance.yahoo.com - March 21 at 5:14 PM
Today’s Research Reports on Trending Tickers: AnaptysBio and Loxo OncologyToday’s Research Reports on Trending Tickers: AnaptysBio and Loxo Oncology
finance.yahoo.com - March 21 at 9:41 AM
Insider Selling: Loxo Oncology Inc (LOXO) VP Sells 1,700 Shares of StockInsider Selling: Loxo Oncology Inc (LOXO) VP Sells 1,700 Shares of Stock
www.americanbankingnews.com - March 15 at 8:10 PM
Loxo Oncology Inc (LOXO) Insider Sells $405,005.62 in StockLoxo Oncology Inc (LOXO) Insider Sells $405,005.62 in Stock
www.americanbankingnews.com - March 15 at 7:46 PM
Loxo Oncology Inc (LOXO) CEO Joshua H. Bilenker Sells 15,000 SharesLoxo Oncology Inc (LOXO) CEO Joshua H. Bilenker Sells 15,000 Shares
www.americanbankingnews.com - March 15 at 7:28 PM
$23.30 Million in Sales Expected for Loxo Oncology Inc (LOXO) This Quarter$23.30 Million in Sales Expected for Loxo Oncology Inc (LOXO) This Quarter
www.americanbankingnews.com - March 14 at 5:54 AM

SEC Filings

Loxo Oncology (NASDAQ:LOXO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Loxo Oncology (NASDAQ:LOXO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Loxo Oncology (NASDAQ LOXO) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.